Utility of Procalcitonin as a Biomarker for Rejection and Differentiation of Infectious Complications in Lung Transplant Recipients

Sammons, Chelsea; Doligalski, Christina T.

doi:10.1177/1060028013508085

Cited by 14 publications

(16 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, PCT is produced in C cells of the thyroid gland and by neuroendocrine cells of the lung and the intestine [12,13]. However, PCT is more a marker for bacterial than for viral infections [14][15][16]. Furthermore, it is possible that we here did not detect any statistical significance because the maximal increase of PCT might be at a later than fours days after OLT.…”

Section: Discussioncontrasting

confidence: 51%

Perioperative White Blood Cell Count as a Marker for Patient and Graft Survival after Orthotopic Liver Transplantation

Helfritz¹,

Lehner²,

Mp³

2015

J Hepatol Gastroint Dis

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 51%

Perioperative White Blood Cell Count as a Marker for Patient and Graft Survival after Orthotopic Liver Transplantation

Helfritz¹,

Lehner²,

Mp³

2015

J Hepatol Gastroint Dis

View full text Add to dashboard Cite

show abstract

“…Studies have shown that PCT can effectively diagnose infectious complication among solid organ transplant recipients [30][31][32]. Unfortunately, these studies were sporadic and there were few analyses focusing on single organ, liver, for example.…”

Section: Discussionmentioning

confidence: 99%

Procalcitonin, a Biomarker for Diagnosing and Differentiating Infection among Liver Transplant Recipients: a systematic review and meta-analysis

Dong

Wan

Zhong

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Infection has long been the major cause for death after liver transplantation. Diagnosing this deadly disease in time can be of great help to support the patients in intensive care units. However, tests like blood culture would take too much time to generate an outcome. Procalcitonin seems to be a promising biomarker in such clinical settings these days. To evaluate its diagnostic value as a biomarker in identifying and differentiating infectious complications in liver transplant recipients. Methods PUBMED, Scopus, Web of Science, Cochrane Library were searched for articles published from January 1990 to September 2019 without language limitation. Cohort or case-control study investigating the value of PCT in distinguishing postoperative infectious complications among liver transplant recipients were included, followed by measurement using QUADAS-2 tool to estimate the risk of bias of each study. Bivariate approach and random-effects model were performed to generate the pooled outcomes. Results 8 studies (studying 560 liver transplant recipients) from 6 populations were reviewed and included, one of which is later excluded due to huge heterogeneity it caused. No significant threshold effect was found, suggesting that heterogeneity returned by the I 2 was not due the various cutoff values. The pooled DOR was 18.65 (95%CI 9.85-35.31) and the area under HSROC was 0.857 ( θ =-0.024; β =-0.203). The positive likelihood ratio and negative likelihood ratio are 3.472 (95% 2.352-5.127) and 0.289 (95% 0.192-0.434). Conclusion Current articles suggest a reasonable diagnostic value for the procalcitonin test in identifying infectious complications among patients undergoing liver transplantation. However, the reason why no threshold effect was found remained explored.

show abstract

“…Blood, plasma or serum: Multiple studies have attempted to identify biomarkers of rejection in the peripheral blood, focusing on cell subsets, proteins, or transcripts. 126,[143][144][145][146] However, most of these studies have been negative or nonreproducible, suggesting that the ACR signal in the peripheral circulation is not detectable using most techniques. A new, more sensitive method to detect donor-derived circulating cell-free DNA (cfDNA) is considered particularly promising for the noninvasive monitoring of allograft injury.…”

Section: Histologic Diagnosismentioning

confidence: 99%

Acute Cellular Rejection: Is It Still Relevant?

Koutsokera

Levy

Pal

et al. 2018

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Despite significant progress in the field of transplant immunology, acute cellular rejection (ACR) remains a very frequent complication after lung transplantation (LTx), with almost 30% of LTx recipients experiencing at least one episode of treated ACR during the first year of follow-up. Most episodes respond to the first-line immunosuppressive treatment and are rarely a direct cause of death. However, the association of ACR with later adverse outcomes, such as chronic lung allograft dysfunction, bronchial stricture, and infectious complications associated with the intensification of immunosuppression, negatively impacts long-term survival. The burden imposed on patients and health-care resources is even higher in cases of refractory or recurrent ACR, which accelerates lung function decline. Although important laboratory and clinical research conducted over the last two decades has improved our understanding of the mechanisms underlying ACR, there are still many uncertainties about the risk factors for ACR, the optimal monitoring strategies, and the prediction of long-term outcomes. These knowledge gaps contribute to the large variability in clinical practice among LTx centers, which renders multicenter studies of ACR challenging. In this review, we summarize current evidence on the epidemiology, pathogenesis, and risk factors of ACR. We describe diagnostic and therapeutic approaches that are currently used in the clinical practice and also review promising diagnostic tools that are under investigation. Associations between ACR and other adverse outcomes of LTx are examined. Finally, within each topic of discussion, we highlight the main areas of controversy and opportunities for future research.

show abstract

Utility of Procalcitonin as a Biomarker for Rejection and Differentiation of Infectious Complications in Lung Transplant Recipients

Cited by 14 publications

References 18 publications

Perioperative White Blood Cell Count as a Marker for Patient and Graft Survival after Orthotopic Liver Transplantation

Perioperative White Blood Cell Count as a Marker for Patient and Graft Survival after Orthotopic Liver Transplantation

Procalcitonin, a Biomarker for Diagnosing and Differentiating Infection among Liver Transplant Recipients: a systematic review and meta-analysis

Acute Cellular Rejection: Is It Still Relevant?

Contact Info

Product

Resources

About